Home
About HIV
Talk to Your Doctor
About KALETRA
Important Corrective Information About KALETRA
Positive Partnership
Paying for Your Medication
Informational Brochures
Medication Guide
Abbott Global

About the Positive Partnership Program

Call 1-888-695-2393 to enroll today.

The Positive Partnership Program was created for people who are taking KALETRA with other HIV medications. Beginning a new therapy isn't always easy, but extra support can make a difference for you. This program provides several tools that may be helpful to you in managing your HIV therapy.

Sign up today

This program is not valid for prescriptions reimbursed under Medicare, Medicaid or similar federal or state programs. In Massachusetts, this offer is not valid for persons eligible for reimbursement of these products in whole or in part by insurance or other 3rd party payer. The KALETRA Positive Partnership Plus Card is not an insurance card.

Use 1

KALETRA® (lopinavir/ritonavir) is a prescription anti-HIV-1 medicine called a protease inhibitor that contains lopinavir and ritonavir. KALETRA is used with other anti-HIV-1 medicines to increase the chance of treatment response in people with human immunodeficiency virus (HIV-1) infection. It is not known if KALETRA is safe and effective in children under 14 days old.

KALETRA does not cure HIV-1 infection or AIDS and does not stop you from passing HIV-1 to others. You may still get opportunistic infections or other conditions that happen with HIV-1.

KALETRA Safety Considerations

Do not take KALETRA if you are allergic to any of its ingredients, including lopinavir or ritonavir. Do not take KALETRA with certain medicines, as they can cause serious problems, death, or make KALETRA less effective against HIV. Some patients taking KALETRA can develop inflammation of the pancreas and liver problems, which can cause death. Patients may develop changes in heart rhythm, large increases in triglycerides and cholesterol, diabetes, high blood sugar, changes in body fat, and/or increased bleeding in people with hemophilia. Some patients may develop signs and symptoms of serious infections they already have after starting anti-HIV medicines.

Click here for Important Safety Information about KALETRA.

The Positive Partnership program is designed to help you work closely with your doctor. Enrolling in the program is simple.

You may also qualify for a KALETRA Positive Partnership Plus Card. With this card, you can save up to $150 on KALETRA and other HIV medications.

The KALETRA Positive Partnership Plus Card offers:

  • Savings up to $50 off the cost of your monthly supply of KALETRA
  • Savings up to $50 each off the cost of other prescribed HIV medications, up to $100

You can save up to $150 per month – for up to 12 months. Ask your doctor about the KALETRA Positive Partnership program.

Tools to help support management of your treatment

Sign up for the Positive Partnership Program and you'll receive information on important topics that affect HIV patients such as:

  • Managing your therapy
  • Diet and exercise
  • HIV and drug resistance

Join the Positive Partnership patient support program and we'll send you a free health planner.

All materials will be sent to you in a plain envelope to protect your privacy.

Sign up today and get support that can help manage your therapy.

Call 1-888-695-2393 to enroll today.

Important Safety Information

Do not take KALETRA if you are allergic to KALETRA or any of its ingredients, including lopinavir or ritonavir. Skin rashes, some of them severe, can occur in people who take KALETRA. Tell your doctor if you had a rash when you took another medicine for HIV or if you notice any skin rash when you take KALETRA.

Drug Interactions:
The list of drug interactions below is not complete. You must tell your doctor about all medicines you are taking or planning to take, including those without a prescription, vitamins, and herbal products.

Serious problems or death can happen if you take these medicines with KALETRA: ergot-containing medicines, including ergotamine (Cafergot® and others), dihydroergotamine (D.H.E. 45® and others), ergonovine (Ergotrate®), and methylergonovine (Methergine®); triazolam (Halcion®); midazolam oral syrup; pimozide (Orap®); lovastatin (Mevacor®); simvastatin (Zocor®); rifampin (Rimactane®, Rifadin®, Rifater®, or Rifamate®); sildenafil (Revatio®) only when used to treat pulmonary arterial hypertension; alfuzosin (Uroxatral®); or products containing St. John’s wort (Hypericum perforatum).

The following medicines may need changes if you take KALETRA: birth control pills that contain estrogen (“the pill”), birth control (contraceptive) patches, nilotinib (Tasigna®) and dasatinib (Sprycel®), atorvastatin (Lipitor®), rosuvastatin (Crestor®), efavirenz (Atripla® and Sustiva®), nevirapine (Viramune®), amprenavir (Agenerase®), fosamprenavir (Lexiva®), nelfinavir (Viracept®), phenytoin (Dilantin®), carbamazepine (Tegretol®), phenobarbital, sildenafil (Viagra®), tadalafil (Cialis®, Adcirca®), vardenafil (Levitra®), rifabutin (Mycobutin®), inhaled fluticasone (Flonase®), salmeterol (Serevent®) and salmeterol in combination with fluticasone propionate (Advair®), colchicine (Colcrys®), bosentan (Tracleer®), fentanyl (Duragesic®, IonsysTM, Fentora®) and methadone.

KALETRA should not be taken once daily if you take carbamazepine (Tegretol® and Epitol®), phenobarbital (Luminal®), or phenytoin (Dilantin®).

There is an increased risk of certain problems when you take medicines used for the treatment of erectile problems such as sildenafil (Viagra®), tadalafil (Cialis®), or vardenafil (Levitra®) with KALETRA, because the interaction with these medicines may result in an increase in their side effects, such as low blood pressure (dizziness or fainting), vision changes, and/or erections lasting more than 4 hours. Tell your doctor right away if you experience any of these side effects.

KALETRA oral solution contains a large amount of alcohol. Talk with your doctor if you take or plan to take metronidazole (Flagyl®) or disulfiram (Antabuse®). You can have severe nausea and vomiting if you take these medicines with KALETRA.

KALETRA can cause serious side effects:
KALETRA may not be right for you. Tell your doctor about all your medical conditions.

Changes in your heart rhythm and the electrical activity of your heart can occur when taking KALETRA. These changes can lead to serious heart problems. Your risk for these problems may be higher if you already have a history of abnormal heart rhythm or other types of heart disease, or if you take other medicines that can affect your heart rhythm while you take KALETRA. Tell your doctor right away if you experience dizziness, lightheadedness, fainting, and/or a sensation of abnormal heartbeats.

Liver problems, including death, can happen in people who take KALETRA. Blood tests in people who take KALETRA may show possible liver problems. People with liver disease such as hepatitis B or C who take KALETRA may have worsening liver disease. People should tell their doctor right away if they have any of the following signs and symptoms: loss of appetite, yellowing of skin or eyes (jaundice), dark-colored urine, pale- colored stools, itchy skin, and/or stomach area (abdominal) pain.

Inflammation of the pancreas (pancreatitis), which may be serious and cause death, has occurred in some people who take KALETRA. You have a higher chance of having pancreatitis if you have had it before. Tell your doctor if you have nausea, vomiting, and/or abdominal pain, as these may be signs of pancreatitis.

Immune reconstitution syndrome may occur after starting anti-HIV medicines, including KALETRA. This happens when you develop signs and symptoms of serious infections you already have, which may require additional treatment.

Large increases in certain fat (triglycerides and cholesterol) levels in the blood have occurred in some people receiving KALETRA. The long-term chance of getting complications such as heart attacks or strokes due to these increases in triglycerides and cholesterol caused by protease inhibitors is not known at this time.

New or more serious diabetes and high blood sugar (hyperglycemia) have occurred in some people who take protease inhibitors, including KALETRA. Tell your doctor if you notice an increase in thirst or urinate often while taking KALETRA.

Changes in body fat have been seen in some people who take anti-HIV therapy. The cause and long-term health effects of these conditions are not known at this time.

Increased bleeding has occurred in some people with hemophilia who take protease inhibitors, including KALETRA.

If you are taking birth control pills or using patches to prevent pregnancy, you should use an extra form or a different type of birth control, since birth control pills or patches may not work as well while you take KALETRA. Talk to your doctor about how to prevent pregnancy while taking KALETRA.

It is not known if KALETRA will harm your unborn baby. If you are pregnant or planning to become pregnant, you should tell your doctor.

If you take KALETRA during pregnancy, you should talk with your doctor about how you can take part in an Antiretroviral Pregnancy Registry. The purpose of the pregnancy registry is to follow the health of you and your baby.

Do not breast-feed while taking KALETRA. There is a chance HIV can be passed to your baby through breast milk and your baby may have serious side effects from KALETRA.

Common side effects of KALETRA include diarrhea, nausea, stomach area (abdominal) pain, feeling weak, vomiting, headache, or upset stomach. These are not all of the possible side effects of KALETRA.

The long-term effects of KALETRA are not known at this time.

This is the most important information to know about KALETRA. For more information, talk with your doctor.

Click here for full Prescribing Information and Medication Guide about KALETRA.

Reference:

  1. Kaletra [package insert]. North Chicago, IL: Abbott Laboratories.

This website and the information contained herein are intended for use by US residents only, are provided for informational purposes only and are not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.


Home | Privacy Policy | Terms of Use | Contact Us
Copyright © 2010 Abbott Laboratories. Abbott Park, Illinois, U.S.A.

039-344703